BrainsWay is an industry leader in the field of transcranial magnetic stimulation (TMS). BrainsWayâs flagship Deep TMS technology is a non-invasive, well-tolerated outpatient treatment, clinically proven to treat psychiatric and neurological conditions. BrainsWay has received FDA-clearance for both major depression (MDD) and obsessive compulsive disorder (OCD- De Novo) and is developing more applications outside of the US. The company also has approval in Japan and other Asian countries. BrainsWay continues to push the TMS envelope with multiple clinical studies and further research into novel indications. BrainsWay has an experienced business and development management team, as well as the backing of key scientific opinion leaders. BrainsWay was founded in 2003 and began trading on the NASDAQ in 2019 under the symbol BWAY. Source
No articles found.
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing th...
Cyclerion Therapeutics is a clinical-stage biop...
Akcea Therapeutics is a development and commercialization company focused on helpi...
Akcea Therapeutics is a development and commerc...
Tandem Diabetes Care, Inc. is a medical device company dedicated to improving the ...
Tandem Diabetes Care, Inc. is a medical device ...
Predictive Oncology is a clinical and translational data pipeline and AI-driven pl...
Predictive Oncology is a clinical and translati...
GEMSS North America is a leading developer, manufacturer & distributor of Digital ...
GEMSS North America is a leading developer, man...
Following two acquisitions of Creagh Medical and NorMedix â recognized innovator...
Following two acquisitions of Creagh Medical an...
Founded in 1996 as a spinoff from the Harvard-MIT Division of Health Sciences and ...
Founded in 1996 as a spinoff from the Harvard-M...
Join the National Investor Network and get the latest information with your interests in mind.